Drug Profile

KUR 503

Alternative Names: CMD-503; CMD-503 CAR-NKT Therapy; KUR-503

Latest Information Update: 16 Apr 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Baylor College of Medicine
Developer Kuur Therapeutics
Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies; NKT cell therapies
Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Discontinued Liver cancer

Most Recent Events

12 Sep 2023 Discontinued - Preclinical for Liver cancer in USA (Parenteral)
22 Mar 2023 9384383; Updated FE also added in KDM
20 Mar 2023 Kuur Therapeutics intention to submit IND application for Liver cancer (Second-line therapy or greater and late stage disease) in 2024

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com